Man Group’s Biogen BIIB Stock Holding History

Man Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-400	Closed	-$84K	–	2069
2022 Q1	$84K	Buy	+400	New	+$87K	﹤0.01%	2075

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Man Group's BIIB Position: Q2 2026 in Review

Man Group reduced its Biogen (BIIB) stake by 38% in Q2 2026, selling an estimated $23.4M and leaving 196,222 shares worth $42.4M. The position accounts for 0.07% of the portfolio, ranked #288.

Man Group first reported a position in BIIB in Q1 2018 and has held it in 31 quarters since. The position peaked at $211M in Q4 2019. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Man Group held 196,222 shares of Biogen worth $42.4M as of Q2 2026.
Man Group sold 122,523 Biogen shares in Q2 2026, an estimated $23.4M.
Biogen made up 0.07% of Man Group's portfolio in Q2 2026, its #288 holding.
Man Group first reported a position in Biogen in Q1 2018 and has held it in 31 quarters since.
Man Group's Biogen position peaked at $211M in Q4 2019.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.